Korean J Psychopharmacol.
2008 Jan;19(1):5-18.
Korean Medication Algorithm for Bipolar Disorder 2006(VI): Comparisons with Other Treatment Guidelines
- Affiliations
-
- 1Department of Psychiatry, Naju National Hospital, Naju, Korea.
- 2Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea. wmbahk@catholic.ac.kr
- 3Department of Psychiatry, Damyang Chamsarang Hospital, Damyang, Korea.
- 4Department of Psychiatry, College of Medicine, Hallym University, Anyang, Korea.
- 5Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea.
- 6Department of Psychiatry, Kangbuk Samsung Hospital, School of Medicine, Sungkyunkwan University, Seoul, Korea.
- 7Department of Psychiatry, College of Medicine, Yonsei University, Seoul, Korea.
- 8Department of Psychiatry, Chonbuk National University Medical School, Jeonju, Korea.
- 9Department of Psychiatry, College of Medicine, Seoul National University, Seoul, Korea.
- 10Department of Psychiatry, College of Medicine, Konkuk University, Cheongju, Korea.
- 11Department of Psychiatry and Stress Research Institute, Seoul Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
- 12Department of Psychiatry, National Health Insurance Corporation Ilsan Hospital, Goyang, Korea.
Abstract
- The Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was developed in 2002 and revised in 2006. The aim of this study was to compare the KMAP-BP 2006 with other recently published treatment guidelines for bipolar disorder. We conducted a systematic review of the six most recently published guidelines and treatment algorithms for bipolar disorder to compare the similarities and differences between these guidelines and the KMAPBP 2006. Most treatment guidelines had similarities in their treatment options. The guidelines generally advocated atypical antipsychotics as first-line treatment in the manic phase and lamotrigine in the depressive phase. While lithium and divalproex were commonly used as mood stabilizers in the manic phase, divalproex was recommended in mixed or dysphoric mania. Mood stabilizers or atypical antipsychotics were selected as first-line treatment in maintenance. Some guidelines were more concerned about special clinical situations such as pregnancy, obesity, metabolic syndrome, and elderly patients, which were not described in the KMAP-BP 2006. Our findings suggest that the medication strategies for bipolar disorder are based on data from recent studies and clinical experiences. Useful information and a rationale for making sequential treatment decisions can be provided by critically reviewing the treatment guidelines. The treatment algorithms and guidelines are not substitutes for clinical judgment, but can serve as critical references to complement individual clinical assessments.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines
- The Development of Korean Medication Algorithm for Major Psychiatric Disorder
- Korean Medication Algorithm for Bipolar Disorder(V): Comparisons with Other Treatment Guidelines
- Comparative Review of Pharmacological Treatment Guidelines for Bipolar Disorder
- Korean Medication Algorithm for Bipolar Disorder 2010: Comparisons with Other Treatment Guidelines
